Design, synthesis and evaluation of dual pharmacology β 2-adrenoceptor agonists and PDE4 inhibitors
L Huang, W Shan, Q Zhou, J Xie, K Lai, X Li
Index: Huang, Ling; Shan, Wenjun; Zhou, Qi; Xie, Jiaxing; Lai, Kefang; Li, Xingshu Bioorganic and Medicinal Chemistry Letters, 2014 , vol. 24, # 1 p. 249 - 253
Full Text: HTML
Citation Number: 9
Abstract
Abstract A novel series of formoterol–phthalazinone hybrids were synthesised and evaluated as dual pharmacology β 2-adrenoceptor agonists and PDE4 inhibitors. Most of the hybrids displayed high β 2-adrenoceptor agonist and moderate PDE4 inhibitory activities. The most potent compound,(R, R)-11c, exhibited agonist (EC 50= 1.05 nM, pEC 50= 9.0) and potent PDE4B2 inhibitory activities (IC 50= 0.092 μM).
Related Articles:
[Givens, Richard S.; Stensrud, Kenneth; Conrad, Peter G.; Yousef, Abraham L.; Perera, Chamani; Senadheera, Sanjeewa N.; Heger, Dominik; Wirz, Jakob Canadian Journal of Chemistry, 2011 , vol. 89, # 3 p. 364 - 384]
Development of an enabling route to PF-00610355: a novel inhaled β2-adrenoreceptor agonist
[De Koning, Pieter D.; Gladwell, Iain R.; Moses, Ian B.; Panesar, Maninder S.; Pettman, Alan J.; Thomson, Nicholas M. Organic Process Research and Development, 2011 , vol. 15, # 6 p. 1247 - 1255]